Author

J. Volovetz

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Approach:experimental assay· 4 Assay:bulk RNA-seq· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell signaling & trafficking· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 1 Organism:Drosophila· 1

Frequent Co-Authors

D. Bayik· 3 shared D. J. Silver· 3 shared J. Lathia· 3 shared E. Mulkearns-Hubert· 2 shared E. S. Hong· 2 shared J. D. Lathia· 2 shared J. Lee· 2 shared M. M. Grabowski· 2 shared

Activity by Year

2018-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

D. Bayik

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

miR-644a is a tumor cell-intrinsic mediator of sex bias in glioblastoma

E. S. Hong, S. Z. Wang, A. K. Ponti, N. Hajdari, J. Lee, E. E. Mulkearns-Hubert, J. Volovetz, K. E. Kay, J. Lathia, A. Dhawan

This study identifies miR-644a as a tumor cell-intrinsic mediator of sex bias in glioblastoma, showing it is more highly expressed in females and its target genes are linked to poorer survival.

bioRxiv · Mar 11, 2024Cancer Biology

Tumor cell-derived spermidine promotes a pro-tumorigenic immune microenvironment in glioblastoma via CD8+ T cell inhibition

K. Kay, J. Lee, E. S. Hong, J. Beilis, S. Dayal, E. R. Wesley, S. Mitchell, S. Z. Wang, D. J. Silver, J. Volovetz, S. Johnson, M. McGraw, M. M. Grabowski, T. Lu, L. Freytag, , J. Lathia

This study shows that spermidine, a metabolite from glioblastoma cells, suppresses CD8+ T cell function, promoting tumor growth and poor patient outcomes.

bioRxiv · Nov 14, 2023Cancer Biology

SerpinB3 drives cancer stem cell survival in glioblastoma

A. Lauko, J. Volovetz, S. M. Turaga, D. Bayik, D. C. Watson, D. J. Silver, K. Mitchell, E. Mulkearns-Hubert, K. Desai, M. Midha, J. Hao, K. McCortney, A. Steffens, U. Naik, M. S. Ahluwalia, , J. D. Lathia

This study identifies SerpinB3 as a key driver of glioblastoma cancer stem cell survival and shows that targeting it enhances radiation therapy efficacy in pre-clinical models.

bioRxiv · Dec 21, 2021Cancer Biology

Identifying conserved molecular targets required for cell migration of glioblastoma cancer stem cells

J. Volovetz, A. D. Berezovsky, T. J. Alban, Y. Chen, G. Aranjuez, A. Burtscher, K. Shibuya, D. J. Silver, J. Peterson, D. Manor, J. McDonald, J. Lathia

This study identifies Rap1a as a conserved regulator of glioblastoma cancer stem cell migration using a combination of Drosophila and human models.

bioRxiv · Jun 13, 2019Cancer Biology

Global immune fingerprinting in glioblastoma reveals immune-suppression signatures associated with prognosis

T. J. Alban, A. G. Alvarado, M. D. Sorensen, D. Bayik, J. Volovetz, E. Serbinowski, E. Mulkearns-Hubert, M. Sinyuk, J. S. Hale, G. R. Onzi, M. McGraw, P. Huang, M. M. Grabowski, C. A. Wathen, T. Radivoyevitch, , J. D. Lathia

The paper identifies immune-suppression signatures in glioblastoma (GBM) patients, showing elevated myeloid-derived suppressor cells (MDSCs) linked to poor prognosis and reduced survival.

JCI Insight · Nov 2, 2018Peer-reviewedCancer Biology